LifePlan Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

LifePlan Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$4K	Buy	+100	New	+$4.32K	﹤0.01%	488

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

LifePlan Financial Group's ACAD Position: Q3 2020 in Review

LifePlan Financial Group opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2020: 100 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #488 among its holdings.

266 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

LifePlan Financial Group held 100 shares of Acadia Pharmaceuticals worth $4K as of Q3 2020.
Acadia Pharmaceuticals was a new LifePlan Financial Group position in Q3 2020.
Acadia Pharmaceuticals made up ﹤0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #488 holding.
266 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.